StockDuty ← Dashboard Oct 28, 2026 06:01 PM ET
SignalCorporate

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Q3 earnings beat and new drug sales drove the tightened 2026 EPS view.

What happened: Biogen reported third-quarter 2026 adjusted EPS of $2.62 and revenues of $2.80 billion, beating Zacks Consensus Estimates on both, and tightened its 2026 adjusted EPS guidance range. Key numbers: Adjusted EPS $2.62 vs. estimate $2.06, down 46% year over year. Why it matters: Growth products including Empaveli, Qalsody, Skyclarys, Spinraza, Syfovre, Zurzuvae and Leqembi collaboration revenues rose almost 50% year over year and surpassed the legacy multiple sclerosis portfolio, while declining MS and biosimilar sales and higher costs weigh on profitability. Market: -1.8% today ($248.25), +39.6% YTD, 0.6x vol — as of 17:47 UTC Verified: Q3_2026 (Oct 28) EPS $2.62 vs $1.98 est, +32.5% beat; next print ~Jan 27
Biogen reported third-quarter 2026 adjusted EPS of $2.62 and revenues of $2.80 billion, beating Zacks Consensus Estimates on both, and tightened its 2026 adjusted EPS guidance range.
Growth products including Empaveli, Qalsody, Skyclarys, Spinraza, Syfovre, Zurzuvae and Leqembi collaboration revenues rose almost 50% year over year and surpassed the legacy multiple sclerosis portfolio, while declining MS and biosimilar sales and higher costs weigh on profitability. Market: -1.8% today ($248.25), +39.6% YTD, 0.6x vol — as of 17:47 UTC Verified: Q3_2026 (Oct 28) EPS $2.62 vs $1.98 est, +32.5% beat; next print ~Jan 27
Sources